Clinical Scorecard: Musings From the Power List: Jason Bock
At a Glance
Category
Detail
Condition
Cell and gene therapy development, with emphasis on cell therapy manufacturing and clinical translation
Key Mechanisms
The author discusses engineered cell therapies, including CAR-T and engineered tumor-infiltrating lymphocyte therapy, and development approaches integrating clinical insight, manufacturing, analytics, automation, and regulatory strategy.
Target Population
Patients with advanced cancers and few or no remaining treatment options; the source does not discuss earlier-line treatment.
Care Setting
Cell therapy research, manufacturing, and oncology clinical development, including INDs and first-in-human studies.
Key Highlights
CTMC reports clearing its tenth IND in collaboration with biotech and academic partners.
The author reports complete responses among patients in some programs supported by CTMC.
The author identifies commercial scalability as a major bottleneck for cell and gene therapies.
The proposed manufacturing direction includes closed systems, robotics, automation, integrated analytics, digital batch records, and process control.
Guideline-Based Recommendations
Diagnosis
Management
The author advocates designing cell therapy products and manufacturing processes for scalability from the beginning.
The author advocates integrating product design, process development, analytics, automation, regulatory strategy, and clinical delivery.
The author advocates moving from artisanal manufacturing toward industrialized approaches, including closed systems, robotics, automation, and integrated analytics.
Monitoring & Follow-up
The author identifies real-time measurement of relevant process parameters and integrated analytics as elements of scalable manufacturing.
Risks
The author says cell therapies may face barriers to broad delivery if they are slow, expensive, variable, labor-intensive, or difficult to deliver reliably across treatment centers.
The author states that manufacturing limitations can constrain a therapy’s ability to scale.
Patient & Prescribing Data
The article refers to patients with advanced cancers and few or no remaining treatment options.
The author reports complete responses among patients in some programs supported by CTMC. No dosing or prescribing details are provided.
Clinical Best Practices
The author advocates pairing speed in clinical translation with rigor, reproducibility, and scalability.
The author advocates assessing whether a therapy can be manufactured consistently and delivered reliably at scale, in addition to evaluating whether it can work in patients.
The author advocates integrating manufacturing and clinical development considerations early in development.
